首页> 美国卫生研究院文献>Molecular Syndromology >Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment
【2h】

Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment

机译:原发性线粒体疾病和继发性线粒体功能障碍:区分诊断和治疗的重要性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Mitochondrial disease refers to a heterogeneous group of disorders resulting in defective cellular energy production due to abnormal oxidative phosphorylation (oxphos). Primary mitochondrial disease (PMD) is diagnosed clinically and ideally, but not always, confirmed by a known or indisputably pathogenic mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) mutation. The PMD genes either encode oxphos proteins directly or they affect oxphos function by impacting production of the complex machinery needed to run the oxphos process. However, many disorders have the ‘mitochondrial’ phenotype without an identifiable mtDNA or nDNA mutation or they have a variant of unknown clinical significance. Secondary mitochondrial dysfunction (SMD) can be caused by genes encoding neither function nor production of the oxphos proteins and accompanies many hereditary non-mitochondrial diseases. SMD may also be due to nongenetic causes such as environmental factors. In our practice, we see many patients with clinical signs of mitochondrial dysfunction based on phenotype, biomarkers, imaging, muscle biopsy, or negative/equivocal mtDNA or nDNA test results. In these cases, it is often tempting to assign a patient's phenotype to ‘mitochondrial disease’, but SMD is often challenging to distinguish from PMD. Fortunately, rapid advances in molecular testing, made possible by next generation sequencing, have been effective at least in some cases in establishing accurate diagnoses to distinguish between PMD and SMD. This is important, since their treatments and prognoses can be quite different. However, even in the absence of the ability to distinguish between PMD and SMD, treating SMD with standard treatments for PMD can be effective. We review the latest findings regarding mitochondrial disease/dysfunction and give representative examples in which differentiation between PMD and SMD has been crucial for diagnosis and treatment.
机译:线粒体疾病是指由于异常的氧化磷酸化(oxphos)而导致细胞能量产生不良的一组异质性疾病。原发性线粒体疾病(PMD)在临床上理想地诊断,但并非总是通过已知或无可争议的致病性线粒体DNA(mtDNA)或核DNA(nDNA)突变来确诊。 PMD基因要么直接编码oxphos蛋白,要么通过影响运行oxphos过程所需的复杂机器的生产来影响oxphos功能。但是,许多疾病具有“线粒体”表型,而没有可识别的mtDNA或nDNA突变,或者具有未知的临床意义。继发性线粒体功能障碍(SMD)可能是由既不编码功能又不产生oxphos蛋白的基因引起的,并伴有许多遗传性非线粒体疾病。 SMD也可能是由于非遗传原因(例如环境因素)引起的。在我们的实践中,我们根据表型,生物标志物,影像学,肌肉活检或mtDNA或nDNA阴性/明确的检测结果,发现许多患有线粒体功能障碍的临床体征的患者。在这些情况下,将患者的表型分配给“线粒体疾病”通常很诱人,但要区分PMD常常是SMD的挑战。幸运的是,至少在某些情况下,下一代测序技术使分子检测的快速进步在建立准确的诊断以区分PMD和SMD方面有效。这很重要,因为他们的治疗和预后可能大不相同。但是,即使没有区分PMD和SMD的能力,用PMD的标准疗法治疗SMD也是有效的。我们回顾了有关线粒体疾病/功能障碍的最新发现,并提供了具有代表性的实例,其中PMD和SMD之间的区别对于诊断和治疗至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号